1. Long-Term Mixed Chimerism After
- Author
-
Ruhnke, Leo, Stölzel, Friedrich, Oelschlägel, Uta, von Bonin, Malte, Sockel, Katja, Middeke, Jan Moritz, Röllig, Christoph, Jöhrens, Korinna, Schetelig, Johannes, Thiede, Christian, and Bornhäuser, Martin
- Subjects
mixed donor chimerism ,allogeneic hematopoietic cell transplantation ,Oncology ,chimerism ,AML ,myeloid neoplasms ,CML ,Original Research - Abstract
In patients who have undergone allogeneic hematopoietic cell transplantation (HCT), myeloid mixed donor chimerism (MC) is a risk factor for disease relapse. In contrast, several studies found favorable outcome in patients with lymphoid MC. Thus far, most studies evaluating MC focused on a short-term follow-up period. Here, we report the first case series of long-term survivors with MC. We screened 1,346 patients having undergone HCT for myeloid neoplasms at our center from 1996 to 2016; 443 patients with data on total peripheral blood mononuclear cells (PBMC)/CD4+/CD34+ short tandem repeat (STR) donor chimerism (DC) and follow-up ≥24 months post-HCT were included. We identified 10 patients with long-term MC (PBMC DC
- Published
- 2021